Trefoil factors are effector molecules in gastrointestinal tract physiology. Each one improves healing of the gastrointestinal tract. Trefoil factors may be grouped into three classes: the gastric peptides (TFF1), spasmolytic peptide (TFF2) and intestinal trefoil factor (TFF3). Signifi cant amounts of TFF3 are present in human breast milk. Previously, we have reported that trefoil factor 3 isolated from human breast milk produces down regulation of cytokines and promotes human beta defensins expression in intestinal epithelial cells. This study aimed to determine the molecular mechanism involved. Here we showed that the presence of TFF3 strongly correlated with protease activated receptors 2 (PAR-2) activation in human intestinal cells. Intracellular calcium ((Ca 2+ )i) mobilization was induced by the treatment with: 1) TFF3, 2) synthetic PAR-2 agonist peptide. The co-treatment with a synthetic PAR-2 antagonist peptide and TFF3 eliminates the latter's effect. Additionally, we demonstrated the existence of interactions among TFF3 and PAR-2 receptors through far Western blot and co-precipitation. Finally, down regulation of PAR-2 by siRNA resulted in a decrease of TFF3 induced intracellular (Ca 2+ )i mobilization, cytokine regulation and defensins expression. These fi ndings suggest that TFF3 activates intestinal cells through PAR-2 (Fig. 4, Ref. 19 ). Text in PDF www.elis.sk.
Introduction
Human breast milk provides nutrients and bio-active factors that may modulate growth and development of the neonate gastrointestinal tract (1) . Human milk constitutes a good source to isolate bio-active peptides and proteins that have been proved to have a favorable role on gut development and immune function (2) . Colostrum and mature-milk contain immunoglobulin A (sIgA), antimicrobial peptides such as defensins, cytokines, and trefoil factors (TFFs). The three main trefoil factors are TFF1, TFF2 and TFF3. Every one of them play a signifi cant role in the conservation and healing of human gastrointestinal tract. Previously we have reported that TFF3 isolated from breast milk produces down regulation of cytokines and defensins (3, 4) . This study aimed to determine the molecular mechanism involved in this process. It has been hypothesized that TFF3 has no specifi c receptor. Other data indicates that intestinal trefoil factor (ITF) can bind to specifi c cell surface proteins and exert biological effects (5, 6) . In this sense, we tested the involvement of protease activated receptors (PARs) in human TFF3 signaling. PARs are integral membrane proteins that are activated by specifi c cleavage of the amino terminal sequence that exposes a new N-terminal sequence functions as a tethered ligand that binds intra-molecularly to activate the receptor (7) . Although the proteolysisis is the main mechanism for PAR activation, it is well known that a synthetic peptide (SLIGKV) that mimics the new N-terminal sequence produced after the cleavage, activates PAR-2 receptors without its proteolytic processing (7) . In this sense, here we report that TFF3 isolated from human breast milk activated PAR-2 receptors of intestinal epithelial cells HT-29.
Materials and methods

Human milk collection
Samples of breast milk were collected within 2-4 weeks postpartum from healthy human mothers (18-30 years old) by manual breast massage. All samples were obtained with an informed consent.
Cultured cells
The HT-29 colonic cell line (passages 5-15) was obtained from the American type of Culture Collection (ATCC, Manassas, USA) and cultured according to the supplier's instructions.
Trefoil factor 3 purifi cation
TFF3 was isolated from human breast milk as previously reported (3).
SDS-PAGE and immunoblotting
Purifi ed TFF3 was subjected to electrophoresis on 15 % SDS-PAGE and immunoblotting as previously reported (3) .
Zymography analysis
10 μg/ml of purifi ed TFF3, or 5 μg/ml of trypsin (positive control) were subjected to SDS-PAGE 15 % acrylamide separating gel containing 1 mg/ml casein, 20 μg/ml BSA, under non reducing conditions. Subsequently, gels were treated twice with 2.5 % Triton X-100, rinsed with water and incubated at 37 °C for 48 h in 50 mM Tris (pH 8.0), 5 mM CaCl 2 . Then, the gels were stained with Coomassie brilliant blue and de-stained in a solution of 25 % ethanol and 10 % acetic acid. Protease activity appeared as clear bands against a blue background.
(Ca
2+
) i measurements The cytosolic Ca 2+ activity ((Ca 2+ )i) was measured in HT29cells using the Ca 2+ -sensitive fl uorescent dye fura-2-AM as previously described (7) . Briefl y, the cells (1000 cells/ml) were seeded onto each cover slip and incubated for 30 min at 37 °C in 1 ml Tyrodesbuffer supplemented with 2 μM fura-2-AM. In some experiments (only cells treated with RNAi), the RNAi treatment was done similarly as above except that the cells were transferred to glass-bottomed 35 mm cell culture dishes before treatment. Forty eight hours after RNAi treatment, the ((Ca 2+ )i) was loaded by the fl uorescent probe fura-2-AM (7). Single-cell fl uorescence measurements of (Ca 2+ )i were done using an imaging system from TILL Photonics GmbH (Munich, Germany). Cells were excited alternately at 340 and 380 nm for 50 ms at each wavelength at the rate of 0.33 Hz and the resulting emission was collected above 510 nm.
NA-interference Assay
siRNAs targeting PAR-2 and PAR-1 were from Santa Cruz Biotechnology (cat. No. sc-36188, and cat. No. sc-36663). HT-29 cells were cultured at 250,000 cells/ml in DMEM with 10 % FBS in 25 cm 2 Falcon culture fl ask, at 37 °C and 5 % CO 2 . After 24 h, the monolayer reached 35-40 % confl uence and was then washed twice with 2 ml of Opti-MEM supplemented with 2 mM CaCl 2 (Opti-MEM-Ca), without FBS. Cells were transfected in 6 ml of Opti-MEM-Ca with 200 nM of the respective synthetic siRNA oligo, employing 0.2 % Lipofectamine-2000 as transfectionagent. 
Far Western-Blot
Total cell lysate from HT-29 containing PAR-2 proteins (prey proteins) were fi rstly separated by 15 % SDS-PAGE, and transferred to a nitrocellulose membrane. The proteins in the membrane were then denatured and renatured in AC buffer by gradually reducing the guanidine -HCl concentration. Membranes were washed 5 times with PBS-tween, blocked for 2 hours in 5 % skim milk in PBS-Tween, and incubated with 10 μg/ml of TFF3 (bait protein) in binding buffer (100 mMNaCl, 20 mMTris (pH 7.6), 0.5 mM EDTA, 10 % glycerol, 0.1 % Tween-20, 2 % skim milk powder) overnight at 4 °C. Bound TFF3 (bait protein) was detected by a primary antibody in a method similar to standard Immunoblotting described above (3) . Membranes were stripped and were reprobed (the reprobed was done using standard immunobloting to determine the position of the PAR-2 (prey proteins) on the membrane).
Co-immunoprecipitation assay
HT-29 cells were incubated with TFF3 (10 μg/ml) by 2 h and whole cell lysates were prepared with 0.2 mL lysis buffer (50 mM Tris-HCl, pH 7.2, 150 mM NaCl, 5 mM EDTA, 0.1 mM DTT, 1 % NP-40, 10 % Glycerol and protease cocktail inhibitor) at 4 °C for 30 min. For immunoprecipitation, the lysates were incubated with 4 μg of an anti-human PAR-2 antibody at RT for 2 h, then mixed with 40 μL of 50 % slurry of protein G-Sepharose and incubated for an additional 2 h. Beads were washed three times with lysis buffer and boiled with 5X SDS loading buffer for 10 min. Western blot using anti-TFF3 as primary antibody was done as described above.
ELISA
We quantifi ed hBDs and cytokines as previously reported (3, 10) .
Reverse transcription polymerase chain reaction (RT-PCR)
RNA was extracted from HT-29 intestinal cells by TrizolTM (Invitrogen) according to the manufacturer's instructions. PCR was done as previously reported (3, 4) .
Results
Trefoil factor 3 (TFF3) purifi cation
Trefoilfactor 3 (TFF3) was purifi ed from human milk by ammonium sulfate precipitation, followed by isolectric precipitation, gel fi ltration and DEAE-Sepharose chromatography (9) (Fig. 1A and 1B). The purity of TFF3 was confi rmed by SDS-PAGE (Fig.  1C ). Our TFF3 preparations contained a band with apparent mass of approximately 7 kDa. That is recognized by anti-TFF3 antibody (Fig. 1D ). We obtained fi ve main fractions in the gel fi ltration chromatography (Fig. 1A) , each fraction was concentrated and underwent to Western blot analysis, just the fi fth fraction (P5) contained the Trefoilfactor 3 ( Fig. 1A, insert) . Then, the P5 fraction ( Fig. 1A ) was concentrated and loaded in DEAE-Sepharose chromatography (Fig. 1B ). After elution with NaCl, the P2 fraction contained the Trefoilfactor 3 purifi ed. Additionally, we tested by immunoblot our TFF3 preparations with an anti-human TFF1 (Fig.  1E ). TFF1 was detected just in clarifi ed human breast milk (total homogenate, lane 1). The proteolytic activity of isolated peptide was analyzed by case in zymography analysis (Fig. 1F, lane 4) . We found that the band observed by SDS-PAGE and immunoblot corresponded to TFF3 purifi ed without proteolytic activity. Finally, we used trypsin as positive control in zymography analysis (Fig. 1F,  lane 5) . Together, the results demonstrate that TFF3 was purifi ed from human breast milk without proteolytic activity.
Secreted-TFF3 activates PAR-2 in HT-29 cells
To evaluate the effect of TFF3 on PAR-2 activation, we explored the epithelial cell response by measuring intracellular Ca 2+ mobilization after exposure of TFF3 or specifi c PAR-2 agonist peptide. As indicated in Figure 2 , both, PAR-2agonist peptide (200 μM, positive control) and TFF3 (10 μg/ml) purifi ed from human breast milk induced a rapid increase in intracellular (Ca 2+ ) in HT-29 intestinal epithelial cells ( Fig. 2A and 2B ). In addition, the treatment with either PAR-2 scrambled agonist peptide (200 μM, negative control) or TFF3 vehicle (Tris-HCl 50 mM, pH 7.2) did not modifi ed the intracellular calcium levels ( Fig. 2C and 2D) . Finally, an analogue of the PAR-2-activating peptide (FSLLRY) has been described to inhibit trypsin-induced activation of PAR-2 (11, 12,) . Therefore, to confi rm the response of PAR-2 to TFF3, we tested regardless the PAR-2 antagonist peptide FSLLRY inhibits the activation of PAR-2 by agonist or TFF3. In our hands, the PAR-2 agonist peptide response was completely inhibited by FSLLRY (200 μM, Fig. 2E ), confi rming that it acts as an effective PAR-2 antagonist on intestinal epithelial cells. This antagonist peptide, FSLLRY (200 μM) blocked the response to TFF3 (10 μg/ ml) (Fig. 2F) , indicating that the variations in (Ca 2+ )i induced by the TFF3 are due to the activation of PAR-2 in epithelial cells.
It is known that intestinal cells HT-29 express other PARs receptors such as PAR-1 (thrombin receptor) (16) . In this sense, we evaluated whether intestinal cells (HT-29) can raise their (Ca 2+ )i after PAR-2 depletion or under the action of PAR-2 antagonist peptide. As indicated in Figure 2 , Thrombin (20 nM, positive control) induced a rapid increase of intracellular (Ca 2+ ) in HT-29 cells (Fig.  2G ) and HT-29 cells pre-treated with PAR-2 antagonist peptide (200 μM). Taken together, these results suggested that intestinal epithelial cells responded to TFF3 by activation of PAR-2 receptor. Finally, to determine the role of G proteins in TFF3 mediated PAR-2 activation, HT-29 cells were pretreated with pertussis toxin (PTX) to uncouple PAR-2 from PTX-sensitive G proteins (7) . PTX pretreatment prevented the increases in (Ca 2+ )i induced by the fragments (Fig. 2H) . Thus, PTX-sensitive G proteins are critically involved in mediating the activation of PAR-2 by TFF3. Taken together, these results showed that the TFF3 fragments, obtained from human milk, activated PAR-2 receptors in HT-29 intestinal epithelial cells.
PAR-2 knockdown inhibits TFF3-induced intracellular calcium mobilization in intestinal epithelial cells HT-29
Previous studies have reported that intestinal epithelial cells HT-29 endogenously express PAR-2 receptors (13). To confi rm the involvement of PAR-2 in TFF3-stimulated intracellular calcium mobilization, HT-29 cells were treated with RNA interference (siRNA) (Santa Cruz Biotechnology, cat. No. sc-36188) to produce specifi c knockdown of PAR-2 receptors. We tested two siRNA concentrations (50 or 200 nM). In this work, we showed that 200 nMof siRNA producedan effi cient knockdown of PAR-2 receptors evaluated by RT-PCR (Fig. 3B, lane 4) , densitometry analysis ( Fig. 3C ) and Western blot (Fig. 3D, lane 4) . Compared with HT-29 cells transfected with control siRNA, cells transfected with the selective siRNA against PAR-2 showed a signifi cant inhibition of the intracellular calcium mobilization stimulated by TFF3 (Fig. 3E) . Finally, HT-29 cells pre-incubated with 200nMof PAR-2 siRNA were treated with thrombin (positive control, 20 nM) in order to verify that HT-29 cells can raise their (Ca 2+ )i after PAR-2 depletion (Fig. 3F) . These results suggested that PAR-2 was involved in TFF3-induced intracellular signaling of HT-29 cells.
PAR2 knockdown inhibits the down regulation of cytokines (IL8 and IL6) and defensins expression (hBD2 and hBD4) induced by TFF3
Previously, we have reported that Trefoilfactor 3 isolated from human breast milk produce down regulation of cytokines (IL-8 and IL-6) and promotes human beta defensins (hBD2 and hBD4) expression in intestinal epithelial cells HT-29 (9) . To confi rm the involvement of PAR-2 in this process, HT-29 cells were treated with RNA interference (siRNA) as described above, and levels of cytokines and defensins were quantifi ed by ELISA. HT-29 cells were grown in 6-well plates at 50 % confl uence and serum-starved for 24 h. Cells were pre-incubated for 24 h with LPS (1 μg/ml), and then treated by 48 h with trefoil 10 μg/ml. As shown in Figure  4 , the levels of IL6 and IL8 (Fig. 4D) after treatment with LPS were signifi cantly higher than in untreated cells. The treatment of HT-29 with TFF3 for 48 h after LPS treatment led to decrease of IL6 and IL8 similar to the basal levels. Finally, the treatment with TFF3 for 48 h after LPS incubation in cells pre-treated with PAR-2 siRNA did not modify the cytokine levels. Together, the results demonstrates that IL6 and IL8 were down-regulated in HT-29 cells treated with TFF3 through PAR-2. Additionally, we directly measured the levels of these antimicrobial peptides in cells culture supernatants after 48 h incubation with TFF3 isolated from human breast milk. HT-29 cells with either LPS or TFF3 for 48 h led to increase of hBD2 and hBD4 concentrations at levels 3-fold higher than in untreated cells (Fig. 4E) . In HT-29 cells pre-treated with siRNA, TFF3 did not modify the defensing levels. Together, the results demonstrated that cytokines and defensins were regulated by TFF3 through the protease activated receptor 2.
Detecting TFF3-PAR-2 interactions by far Western blotting and co-immunoprecipitation
To further demonstrate the existence of interactions between TFF3 and PAR-2 receptors, far Western blot assay (Figs 4A-B) and co-immunoprecipitation (Fig. 4C) were done. In far Western blot assay, proteins in a cell lysate from HT-29 containing PAR-2 were fi rstly separated by SDS-PAGE, and transferred to a nitrocellulose membrane. Then, proteins in the membrane were denatured, renatured, blocked, and probed with purifi ed TFF3. Finally, TFF3 proteins were detected on spots in the membrane where PAR-2 receptors were located because the TFF3 protein and PAR-2 together formed a protein complex. We found that TFF3 associated with PAR-2 (Fig. 4A, lane 1) . Then, membranes were stripped and reprobed using standard immunoblotting to determine the position of the PAR-2 proteins on the membrane (Fig. 4A, lane 2) . PAR-2 protein bands are shown around 44 kDa (7). The higher bands are un-cleaved PAR-2 and the lower bands are cleaved PAR-2 as previously reported (14) . Then, we tested if primary antibody anti-TFF3 (Santa Cruz Biotechnology, cat. No. sc-28927) bound non-specifi cally to cell lysate from HT-29 through Western blot assay. We found that anti-TFF3 did not bind to any proteins contained in HT-29 (Fig. 4A, lane 3) . Additionally, far Western blot assay in cells treated with siRNA was done (Fig 4B) . We tested two siRNA concentrations (50 or 200 nM,). In this assay, we showed that TFF3 associated with PAR-2 (Fig. 4B, lane 1) . Then, HT-29 cells treated with 200 nMof PAR-2 siRNA produced a decrease between TFF3-PAR-2 association (Fig 4B, lane 4) . This result suggested that PAR-2 bound to TFF3, and the specifi c PAR-2 knock-down inhibited the interaction between PAR-2 and TFF3. Finally, to further demonstrate that TFF3 binds to PAR-2, co-immunoprecipitation assay was done (Fig 4C) . HT-29 cells were incubated with TFF3 (10 μg/ml) by 2 h. Then, the cells were treated with lysis buffer and cell lysates were immunoprecipitated with antibodies directed to PAR-2 (lanes 2-5). Immunoprecipitated were analyzed by Western blotting using anti-TFF3 antibody. TFF3 was only detected in the pellet fraction from cells lysates immunoprecipitated with anti-PAR-2, confi rming that TFF3 interacted with PAR-2 in vitro (lane 2). In cells pre-treated with PAR-2 siRNA, TFF3 was not detected (lane 3). Additionally, Figure 4C , lane 1 shows 10 μg/ml of TFF3 purifi ed (Positive control). Finally, negative control were carried out: Cells lysates from HT-29 without immunoprecipitation with anti-PAR-2 (lane 4), and HT-29 cells lysates without TFF3 treatment (lane 5).Taken together, these data indicated that TFF3 bound to PAR2.
Discussion
Trefoil peptides are found along the gastrointestinal tract and play a central role in the physiology of the gut (15). In this work, we showed that TFF3 activated PAR-2 to produce intracellular signaling that resulted in cytokine and defensins regulation in HT-29 cells. Defensins are cysteine-rich, cationic peptides with β-pleated sheet confi gurations that are stabilized generally by three disulphide bonds. Human defensins are grouped in three subfamilies, theα-, β-and θ-defensins. The beta-defensin family is produced by epithelial cells and plays an important role in mucosal defense against luminal microbes (16) . The recent report showed that frog TFF2 activated protease-activated receptor 1 (PAR-1) to induce human platelet aggregation (6) . Based on this result, we further tested the involvement of PAR-2 in human TFF3-promoted defensins and cytokines regulation (3). Two main mechanisms has been described for the activation of PAR-2: (1) by specifi c cleavage that unmask the receptor-activating peptide sequence present in the extracellular N-terminal domain of each PAR, leading to cell signaling via interaction of the exposed tethered ligand with the body of the receptor itself; and (2) by synthetic peptides, such as SLIGKV, that bind to the receptor, mimicking the actions of agonist proteases. In this work, we eliminated the fi rst mechanism of activation by receptor proteolyisis because we isolated TFF3 from human breast milk without proteolytic activity (Fig. 1F) . Subsequent, we speculated that the second activation mechanism was involved in this process. Several observations in our work suggested that TFF3 was a potential agonist of PAR-2. First, TFF3 isolated from human breast milk increased (Ca 2+ )i in HT-29 intestinal epithelial cells. Second, the responses to TFF3 were abolished by incubating cells with a specifi c PAR-2 antagonist peptide (FSLLRY, 200 μM) or pre-incubating cells with PTX, which is consistent with the idea that PAR-2 mediates the cellular response to TFF3. Moreover, the specifi c knockdown of PAR-2 receptors by siRNA blocked the activation of PAR-2 normally induced by both the agonist peptide (positive control) and TFF3.
We found that TFF3 isolated from human breast milk was more able to induce intracellular Ca 2+ mobilization than PAR-2 agonist peptide, a mimic of the PAR-2 tethered ligand. The concentration (1.25 nM = 10 μg/ml) of TFF3 required was 160.000-fold lower than PAR-2-agonist peptide (200 μM) to produce similar Ca 2+ mobilization response in intestinal epithelial cells HT-29 (Fig.  2) . These results suggested that multiple binding sites might be involved in the interaction of TFF3 with PAR-2 to increase the binding affi nity and/or activating effi ciency. In this sense, because a lower concentration of TFF3 may activate PAR-2, we speculated that PAR-2 might be one of the natural intestinal receptors for TFF3 isolated from human milk. G-proteins coupled receptors (GPCR) often appear to assemble into dimmers, which have been shown to modulate ligand affi nity and signal transduction (17) . It also has been shown that dimmers of single-domain TFFs, such as TFF1, were biologically more potent than the monomers (18) . TFF3 is usually a homodimmer and could act as a bivalent ligand. It is possible that TFF3 binds to and activates the dimeric form of PAR-2 to stimulate cell signaling. In this work, we showed a direct interaction between PAR-2 of intestinal epithelial cells and TFF3 isolated from human milk (Fig. 4) . The TFF3 shares a completely conserved distinctive motif of six cysteine residues, which form three disulfi de bonds and defi ne the "trefoil" domain, which is also known as a 'P' domain (19) . We speculated that every loops contained in trefoil factor 3 could play an important role in the binding of TFF3 and PAR-2.
There are several new fi ndings of this study. First, we presented the head evidence of human putative intestinal receptor for TFF3 isolated from human milk. Second, PAR-2 knockdown by siRNA inhibited TFF3-induced intracellular signaling in intestinal epithelial cells HT-29. Third, the cytokine regulation and defensins expression were through PAR-2 expressed in intestinal cells. This work supported the hypothesis that during lactation, TFF3 secreted in human milk may activate intestinal epithelial cells through PAR-2 receptors, which in turn induces hBD2 and hBD4 expression and cytokine regulation.
